文献速递神经肿瘤

端粒酶逆转录酶启动子突变在脑膜瘤中的预后意义:系统综述与Meta分析

The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
PubMed 文献 · J Neurooncol · 2018-12-01

该系统综述与Meta分析纳入5项回顾性观察性队列研究、共532例脑膜瘤患者,评估端粒酶逆转录酶启动子(TERTp)突变的预后意义。TERTp突变发生率为8%,与显著更差预后(HR 3.79;P=0.005)及显著更短总生存期(均数差59.8个月;P=0.037)相关。作者认为早期识别该亚组可能支持更频繁随访和积极管理以优化生存结局。

要点

  • 脑膜瘤中TERTp突变发生率为8%,与显著更差预后相关(HR 3.79;P=0.005)。
  • TERTp突变与显著更短总生存期相关(均数差59.8个月;P=0.037)。
  • 脑膜瘤分级与TERTp突变效应无显著关联,但Meta回归趋势提示统计学效能增大后可能显著。

核心结论

  • 当前证据表明脑膜瘤中存在TERTp突变可能与更差预后及更短总生存期相关。
  • 作者认为在管理中早期识别该脑膜瘤患者亚组,可能支持更频繁随访和积极管理以优化生存结局。

研究设计与样本

  • 系统综述与Meta分析,检索7个电子数据库自建库至2018年9月,初筛227篇文章。
  • 最终纳入5项回顾性观察性队列研究,共描述532例脑膜瘤患者。
  • 采用固定效应和随机效应模型合并风险比(HR)与均数差(MD),并行Meta回归探索异质性来源。

主要发现

  • TERTp突变发生率为8%。
  • 随机效应模型显示TERTp突变与显著更差预后相关(HR 3.79;P=0.005)。
  • 随机效应模型显示TERTp突变与显著更短总生存期相关(均数差59.8个月;P=0.037)。
  • 脑膜瘤分级与TERTp突变效应无显著关联,但初步Meta回归趋势提示获得更大统计学效能后可能显著。

临床怎么用

  • 作者认为在管理中早期识别TERTp突变的脑膜瘤患者亚组,可能支持更频繁随访和积极管理以优化生存结局。

局限性

  • 纳入研究均为回顾性观察性队列研究。
  • TERTp突变发生率基于532例患者的合并数据为8%。
  • 脑膜瘤分级与TERTp突变效应无显著关联,但初步Meta回归趋势提示需更大统计学效能才能判断其是否显著。
  • 作者指出需在更大数量中常规检测以进一步验证,并阐明不同组织学分级的效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutations in the telomerase reverse transcriptase promoter (TERTp) region have been associated with worse prognosis in some cancers. Meningiomas are the most common type of primary central nervous tumors, and evaluation of the prognostic significance of TERTp mutations across the literature is lacking. The aim of this study was to pool all current evidence to assess for clinical relevance of TERTp mutations in meningioma and survival effect. METHODS: Searches of seven electronic databases from inception to September 2018 were conducted following the appropriate guidelines. Two hundred and twenty seven articles were identified for screening. Hazard ratio (HR) and mean difference (MD) statistics were obtained and pooled utilizing both fixed- and random-effect (RE) models. Meta-regression was utilized to determine potential sources of heterogeneity and statistical influence. RESULTS: A total of five retrospective observational cohort studies describing 532 meningioma patients satisfied selection criteria. The incidence of TERTp mutations was 8%, and was associated with significantly worse prognosis (HR 3.79; P = 0.005) and significantly shorter overall survival (MD 59.8 months; P = 0.037) by RE modelling. Meningioma grade was not significantly associated with a TERTp mutation effect, however, preliminary meta-regression trends indicated this may be significant once greater statistical power is achieved. CONCLUSION: The current evidence indicates the presence of a TERTp mutation in meningioma can be associated with worse prognosis, and shorter overall survival. Routine detection in greater numbers will allow for further validation, as well as delineate the effect across histological grades. By identifying this subgroup of meningioma patients early in management, it may support more frequent follow-up and aggressive management to optimize survival outcomes.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lu VM, Goyal A, Lee A, et al. The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis. J Neurooncol. 2018. PMID: 30506498. doi:10.1007/s11060-018-03067-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。